Pharmaceutical Executive-11-01-2022

A shift in mindset to the experiment itself could lead the way.

Why enabling a shared culture of quality across an organization is key to maintaining pharma’s recent pace of innovation wins—while inspiring new levels of confidence.

Senior leaders focused on the advancement of digital medicine and health meet to discuss the importance of these tools for life sciences companies, payers, and others in harnessing a healthcare future that will be increasingly dominated by holistic treatment and delivery.

Christi Shaw, CEO of Kite, is working hard to bring cell therapy to the masses, fueled by her family’s personal experiences with cancer.

Focus is on cash: who’s got it, who doesn’t, and what will it mean?

The validity of ESG-driven investment and reporting in healthcare.

AI drives new signal-detection efforts in Alzheimer’s and ALS.

Making sense of surprise rejection of draft proposals.

Executives share insights at recent conferences.

Click the title above for a link to open the Pharmaceutical Executive November 2022 issue in an interactive PDF format.

The ‘skinny’ user fee reauthorization tables multiple high-profile proposals.